CAR T-Cell Therapy Results in Remission for Myeloma Patients
In a study posted online by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer.
Patient education resource: Immunotherapy education session
View this resource for further information on what to do before starting immunotheraphy treatment.
Cancer Immunotherapy: 2021 Research and Look Ahead - Webinar for patrients and c...
CRI Scientific Advisory Council Associate Director Dr. Kunle Odunsi discusses the future of cancer immunotherapy and what may lie aheads for the field.
Latest News on CAR T-Cell Therapy for Multiple Myeloma
How can CAR T-cell therapy be used to treat multiple myeloma, and what is the latest in CAR T-cell research? Is it getting closer to being an approved treatment option? What are we learning from clinical trials? And finally, what should patients know?
Multiple Myeloma Roundtable: Immunotherapies & MRD Debate
Each year during the ASH Annual Meeting & Exposition, Patient Power brings together several of the world’s leading experts in multiple myeloma for a roundtable discussion of the latest myeloma research and news. Hear from three renowned experts and Patient Power co-founder Andrew Schorr as they discuss the state of multiple myeloma treatment today including advances in immunotherapy, new promising drug options, the role of minimal residual disease (MRD) testing in determining treatment paths, and other important topics including disparities in multiple myeloma care.
Comparing CAR-NK and CAR T-Cell Therapies
How Do Chimeric Antigen Receptor (CAR) Therapies Differ? Dr. Katy Rezvani, Chief, Section of Cellular Therapy, Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center joins Patient Power Co-founder Andrew Schorr to explain the difference between the two new cell therapies and what this innovation means for ALL, CLL, and NHL patients.
ASH 2020 MPN Roundtable: Individualized Treatment Plans
What are the key takeaways in myeloproliferative neoplasm (MPN) research from ASH 2020? How have immunotherapy treatments advanced? Are there any promising new clinical trials? And finally, among so many options for MPN treatment, how can you and your care team create an individualized treatment plan that is right for you? Hear four of the world's leading MPN experts answer these questions and more with host and MPN patient advocate Ruth Fein.
It’s All About the Antibodies! How mAbs work in Multiple Myeloma
"To understand how a monoclonal antibody works first you need to know what an antigen is. An antigen is a molecule that is able to generate antibodies in our immune system." - Read this review by Cindy Chmielewski on the mechanism of action (how they work) of each type of antibody.
A Hodgkin Lymphoma Patient Discusses the Phase I Clinical Trial that Saved Her L...
In this podcast, you will hear a fireside discussion from the 2020 IO360° Summit featuring cancer survivor and advocate, Ariella Chivil who walked the audience through her immunotherapy trial pathway alongside patient advocate, Cindy Geoghegan, who moderated the chat.
Patient Perspectives on Cancer Immunotherapy at the 2020 CRI Virtual Immunothera...
At the 2020 CRI Virtual Immunotherapy Patient Summit, three CRI ImmunoAdvocates—cancer veterans treated with immunotherapy— share their experiences with cancer, immunotherapy, health care, and support.